Yasuhiko Nishioka

ORCID

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 19

Top Venues

Thoracic cancer

Cancer science

ERJ open research

Immunity, inflammation and disease

This page only lists publications with an associated author ORCID identifier.

Publications

Toby M Maher, R Gisli Jenkins, Vincent Cottin, Yasuhiko Nishioka, Imre Noth, Moisés Selman, Jin Woo Song, Carina Ittrich, Claudia Diefenbach, Susanne Stowasser, Eric S White
Circulating biomarkers and progression of idiopathic pulmonary fibrosis: data from the INMARK trial. ERJ open research 10 (4) (2024)
Toby M Maher, R Gisli Jenkins, Vincent Cottin, Yasuhiko Nishioka, Imre Noth, Moisés Selman, Jin Woo Song, Carina Ittrich, Claudia Diefenbach, Susanne Stowasser, Eric S White
Circulating biomarkers and progression of idiopathic pulmonary fibrosis: data from the INMARK trial. ERJ open research 10 (4) (2024)
Hiroto Yoneda, Atsushi Mitsuhashi, Aito Yoshida, Hirokazu Ogino, Satoshi Itakura, Na Thi Nguyen, Hiroshi Nokihara, Seidai Sato, Tsutomu Shinohara, Masaki Hanibuchi, Shinji Abe, Mika K Kaneko, Yukinari Kato, Yasuhiko Nishioka
Antipodoplanin antibody enhances the antitumor effects of CTLA-4 blockade against malignant mesothelioma by natural killer cells. Cancer science 115 (2) (2023)
Hiroyuki Kozai, Hirokazu Ogino, Atsushi Mitsuhashi, Na Thi Nguyen, Yuki Tsukazaki, Yohei Yabuki, Ryohiko Ozaki, Hiroto Yoneda, Seidai Sato, Masaki Hanibuchi, Tsutomu Shinohara, Hiroshi Nokihara, Yasuhiko Nishioka
Potential of fluoropyrimidine to be an immunologically optimal partner of immune checkpoint inhibitors through inducing immunogenic cell death for thoracic malignancies. Thoracic cancer 15 (5) (2023)
Hiroyuki Kozai, Hirokazu Ogino, Atsushi Mitsuhashi, Na Thi Nguyen, Yuki Tsukazaki, Yohei Yabuki, Ryohiko Ozaki, Hiroto Yoneda, Seidai Sato, Masaki Hanibuchi, Tsutomu Shinohara, Hiroshi Nokihara, Yasuhiko Nishioka
Potential of fluoropyrimidine to be an immunologically optimal partner of immune checkpoint inhibitors through inducing immunogenic cell death for thoracic malignancies. Thoracic cancer (2023)
Eiji Takeuchi, Kensuke Kondo, Yoshio Okano, Seiya Ichihara, Michihiro Kunishige, Naoki Kadota, Hisanori Machida, Nobuo Hatakeyama, Keishi Naruse, Hirokazu Ogino, Hiroshi Nokihara, Tsutomu Shinohara, Yasuhiko Nishioka
Pretreatment eosinophil counts as a predictive biomarker in non-small cell lung cancer patients treated with immune checkpoint inhibitors. Thoracic cancer (2023)
Hiroyuki Kozai, Hirokazu Ogino, Atsushi Mitsuhashi, Na Thi Nguyen, Yuki Tsukazaki, Yohei Yabuki, Ryohiko Ozaki, Hiroto Yoneda, Seidai Sato, Masaki Hanibuchi, Tsutomu Shinohara, Hiroshi Nokihara, Yasuhiko Nishioka
Potential of fluoropyrimidine to be an immunologically optimal partner of immune checkpoint inhibitors through inducing immunogenic cell death for thoracic malignancies. Thoracic cancer 15 (5) (2023)
Eiji Takeuchi, Hirokazu Ogino, Kensuke Kondo, Yoshio Okano, Seiya Ichihara, Michihiro Kunishige, Naoki Kadota, Hisanori Machida, Nobuo Hatakeyama, Keishi Naruse, Hiroshi Nokihara, Tsutomu Shinohara, Yasuhiko Nishioka
An increased relative eosinophil count as a predictive dynamic biomarker in non-small cell lung cancer patients treated with immune checkpoint inhibitors. Thoracic cancer (2023)
Hiroto Yoneda, Atsushi Mitsuhashi, Aito Yoshida, Hirokazu Ogino, Satoshi Itakura, Na Thi Nguyen, Hiroshi Nokihara, Seidai Sato, Tsutomu Shinohara, Masaki Hanibuchi, Shinji Abe, Mika K Kaneko, Yukinari Kato, Yasuhiko Nishioka
Antipodoplanin antibody enhances the antitumor effects of CTLA-4 blockade against malignant mesothelioma by natural killer cells. Cancer science 115 (2) (2023)
Hiroyuki Kozai, Hirokazu Ogino, Atsushi Mitsuhashi, Na Thi Nguyen, Yuki Tsukazaki, Yohei Yabuki, Ryohiko Ozaki, Hiroto Yoneda, Seidai Sato, Masaki Hanibuchi, Tsutomu Shinohara, Hiroshi Nokihara, Yasuhiko Nishioka
Potential of fluoropyrimidine to be an immunologically optimal partner of immune checkpoint inhibitors through inducing immunogenic cell death for thoracic malignancies. Thoracic cancer 15 (5) (2023)
Yohei Yabuki, Masaki Hanibuchi, Eiji Takeuchi, Takashi Haku, Takanori Kanematsu, Naoki Nishimura, Yuko Toyoda, Atsushi Mitsuhashi, Kenji Otsuka, Seidai Sato, Hisatsugu Goto, Hiroto Yoneda, Hirokazu Ogino, Hiroshi Nokihara, Shinohara Tsutomu, Yasuhiko Nishioka
A multicenter, open-label, phase II trial of pemetrexed plus bevacizumab in elderly patients with previously untreated advanced or recurrent nonsquamous non-small cell lung cancer. Thoracic cancer (2023)
Hiroto Yoneda, Atsushi Mitsuhashi, Aito Yoshida, Hirokazu Ogino, Satoshi Itakura, Na Thi Nguyen, Hiroshi Nokihara, Seidai Sato, Tsutomu Shinohara, Masaki Hanibuchi, Shinji Abe, Mika K Kaneko, Yukinari Kato, Yasuhiko Nishioka
Antipodoplanin antibody enhances the antitumor effects of CTLA-4 blockade against malignant mesothelioma by natural killer cells. Cancer science 115 (2) (2023)
Hiroto Yoneda, Atsushi Mitsuhashi, Aito Yoshida, Hirokazu Ogino, Satoshi Itakura, Na Thi Nguyen, Hiroshi Nokihara, Seidai Sato, Tsutomu Shinohara, Masaki Hanibuchi, Shinji Abe, Mika K Kaneko, Yukinari Kato, Yasuhiko Nishioka
Antipodoplanin antibody enhances the antitumor effects of CTLA-4 blockade against malignant mesothelioma by natural killer cells. Cancer science (2023)
Na T Nguyen, Atsushi Mitsuhashi, Hirokazu Ogino, Hiroyuki Kozai, Hiroto Yoneda, Tania Afroj, Seidai Sato, Hiroshi Nokihara, Tsutomu Shinohara, Yasuhiko Nishioka
S-1 eliminates MDSCs and enhances the efficacy of PD-1 blockade via regulation of tumor-derived Bv8 and S100A8 in thoracic tumor. Cancer science (2022)
Kenji Otsuka, Hiroshi Nokihara, Atsushi Mitsuhashi, Ryohiko Ozaki, Yohei Yabuki, Hiroto Yoneda, Hirokazu Ogino, Yasuhiko Nishioka
Efficacy and safety of second-line chemotherapy for patients with advanced non-small cell lung cancer complicated by interstitial lung disease. Thoracic cancer 13 (21) (2022)
Yutaka Morita, Atsuro Saijo, Hiroshi Nokihara, Atsushi Mitsuhashi, Hiroto Yoneda, Kenji Otsuka, Hirokazu Ogino, Yoshimi Bando, Yasuhiko Nishioka
Radiation therapy induces an abscopal effect and upregulates programmed death-ligand 1 expression in a patient with non-small cell lung cancer. Thoracic cancer 13 (7) (2022)
Atsushi Mitsuhashi, Kensuke Kondoh, Kazuki Horikawa, Kazuya Koyama, Na Thi Nguyen, Tania Afroj, Hiroto Yoneda, Kenji Otsuka, Hirokazu Ogino, Hiroshi Nokihara, Tsutomu Shinohara, Yasuhiko Nishioka
Programmed death (PD)-1/PD-ligand 1 blockade mediates antiangiogenic effects by tumor-derived CXCL10/11 as a potential predictive biomarker. Cancer science 112 (12) (2021)
Masahiro Sako, Hiroshi Nokihara, Kensuke Kondo, Atsushi Mitsuhashi, Ryohiko Ozaki, Yohei Yabuki, Akane Abe, Hiroto Yoneda, Hirokazu Ogino, Kenji Otsuka, Hisanori Uehara, Yasuhiko Nishioka
A case of pulmonary pleomorphic carcinoma with preexisting interstitial pneumonia successfully treated with pembrolizumab. Thoracic cancer (2021)
Hiroshi Kawano, Kazuya Koyama, Haruka Nishimura, Yuko Toyoda, Kozo Kagawa, Seidai Sato, Nobuhito Naito, Hisatsugu Goto, Yutaka Inagaki, Yasuhiko Nishioka
Development of improved method to identify and analyze lung fibrocytes with flow cytometry in a reporter mouse strain. Immunity, inflammation and disease 9 (1) (2020)

Yasuhiko Nishioka.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Yasuhiko Nishioka